The route to personalized medicine in bladder cancer: where do we stand?

S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy

(2014) W. T. Kim et al.   ANNALS OF ONCOLOGY

Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition

(2014) Yifeng Jing et al.   CANCER LETTERS

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

(2014) S. Rebouissou et al.   Science Translational Medicine

Phase II study of everolimus in metastatic urothelial cancer

(2013) Matthew I. Milowsky et al.   BJU INTERNATIONAL

Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells

(2013) Jörg Hänze et al.   BMC CANCER

Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells

(2013) M Santoni et al.   BRITISH JOURNAL OF CANCER

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

(2013) Petros D. Grivas et al.   CANCER

The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo

(2013) N. Zhou et al.   CLINICAL CANCER RESEARCH

A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

(2013) Roberto Pili et al.   Clinical Genitourinary Cancer

Biomarkers in bladder cancer: Translational and clinical implications

(2013) Liang Cheng et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer

(2013) Gopa Iyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular targets on the horizon for kidney and urothelial cancer

(2013) Joaquim Bellmunt et al.   Nature Reviews Clinical Oncology

BRAF inhibitors in cancer therapy

(2013) Carolina Hertzman Johansson et al.   PHARMACOLOGY & THERAPEUTICS

The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro

(2013) Marie N. Becker et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer

(2012) Matthew D. Galsky et al.   Clinical Genitourinary Cancer

microRNA expression profile in a large series of bladder tumors: Identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer

(2012) Géraldine Pignot et al.   INTERNATIONAL JOURNAL OF CANCER

PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs

(2012) R L Ross et al.   ONCOGENE

Vascular Endothelial Growth Factor, Carbonic Anhydrase 9, and Angiogenin as Urinary Biomarkers for Bladder Cancer Detection

(2012) Virginia Urquidi et al.   UROLOGY

Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours

(2011) Achim Fleischmann et al.   EUROPEAN UROLOGY

Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75

(2011) Noah M. Hahn et al.   JOURNAL OF CLINICAL ONCOLOGY

Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder

(2011) Kunyoo Shin et al.   NATURE

Cyclooxygenase 2-dependent and independent activation of Akt through casein kinase 2α contributes to human bladder cancer cell survival

(2011) Keiji Shimada et al.   BMC Urology

Altered Splicing of FGFR1 Is Associated with High Tumor Grade and Stage and Leads to Increased Sensitivity to FGF1 in Bladder Cancer

(2010) Darren C. Tomlinson et al.   AMERICAN JOURNAL OF PATHOLOGY

Cancer stem cells in bladder cancer: a revisited and evolving concept

(2010) Keith Syson Chan et al.   CURRENT OPINION IN UROLOGY

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

(2010) Srikala S. Sridhar et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer

(2010) David J. Gallagher et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting cancer stem cells by inhibiting Wnt, Notch and Hedgehog pathways

(2010) Naoko Takebe et al.   Nature Reviews Clinical Oncology

Implication of RAF and RKIP Genes in Urinary Bladder Cancer

(2010) Apostolos Zaravinos et al.   PATHOLOGY & ONCOLOGY RESEARCH

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

(2009) M. Lae et al.   ANNALS OF ONCOLOGY

Phase 2 trial of sorafenib in patients with advanced urothelial cancer

(2009) Robert Dreicer et al.   CANCER

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

(2009) Christian Wülfing et al.   CANCER

Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer

(2009) David J. McConkey et al.   CANCER AND METASTASIS REVIEWS

Urothelial carcinoma: Stem cells on the edge

(2009) William D. Brandt et al.   CANCER AND METASTASIS REVIEWS

Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer

(2009) D. C. Tomlinson et al.   CANCER RESEARCH

Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer

(2009) J. W.F. Catto et al.   CANCER RESEARCH

miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy

(2009) L. Adam et al.   CLINICAL CANCER RESEARCH

Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion

(2009) Manoj Garg et al.   EUROPEAN JOURNAL OF CANCER

Activation of RAS Family Genes in Urothelial Carcinoma

(2009) I. Boulalas et al.   JOURNAL OF UROLOGY

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations

(2009) Maria Karlou et al.   PATHOLOGY

Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas

(2009) Gamze Donmez et al.   PATHOLOGY RESEARCH AND PRACTICE

Angiogenic Switch of Angiopietins-Tie2 System and Its Prognostic Value in Bladder Cancer

(2008) T. Szarvas et al.   CLINICAL CANCER RESEARCH

Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study

(2008) Maximilian Burger et al.   EUROPEAN UROLOGY

FGFR3 Mutations Indicate Better Survival in Invasive Upper Urinary Tract and Bladder Tumours

(2008) Johanna M.M. van Oers et al.   EUROPEAN UROLOGY

The development of multiple bladder tumour recurrences in relation to theFGFR3mutation status of the primary tumour

(2008) Lucie C Kompier et al.   JOURNAL OF PATHOLOGY